Research article · 14 Apr 2026
Conference abstractPublished 6 Oct 2017
Targeting RNA binding proteins: A versatile platform for the discovery and development of new antivirals
University of Montpellier, France
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
ABX464 is a first-in-class, novel, small molecule inhibiting HIV replication through an entirely new mechanism of action. For the first time in the treatment of HIV, this molecule could reduce or eliminate the viral reservoirs, and thus potentially deliver a long lasting reduction in the viral load of HIV-patients., ABIVAX designed ABX464 with the goal of targeting the viral reservoirs of immune cells with integrated genetic material from the HIV-virus. These reservoirs are not affected by current antiretroviral therapies, and lead to viral load rebound once treatment is stopped. ABX464 inhibits the biogenesis of viral RNA required for the replication of the HIV virus by targeting the Cap Binding Complex (CBC). During replication HIV RNA is first spliced to give rise to spliced RNA from which essential auxiliary proteins, like Rev and Tat proteins, are synthesized but later during infection unsliced viral RNA are produced to generate structural protein and viral genome. ABX464 by stabilizing CBC complex on HIV RNA prevent the synthesis of unspliced RNA. This unique mode of action and the preclinical data to-date suggest that ABX464 has the potential to: Reduce or eliminate the viral reservoirs in patients with HIV Induce long term control of the viral load Prevent the emergence of HIV mutants that are resistant to treatment Be less frequently administered over a shorter period than standard treatments Reduce healthcare costs and offer broader access to treatment. ABX464 is the first candidate molecule coming from ABIVAXâÂ?Â?s proprietary antiviral platform and chemical library. This library of more than one thousand small molecules targets the formation of RNPâÂ?Â?s in the nucleus or the cytoplasm of the infected cell during viral infection. Indeed, to replicate, viruses need to generate RNA-Protein complexes (RNP) from the host cell material. RNP complexes are composed of viral RNA and cellular and viral proteins. Those complexes can âÂ?Â?hijackâÂ? the cellular machinery of the host cells to express viral RNA and generate new viruses. This approach can be applied to any type of viruses. ABX311 is the second molecule coming from the ABIVAX antiviral platform. ABX311 is a small molecule able to inhibit Chikungunya viral replication in vitro with an IC50 in the nanomolar range. ABX311 will enter preclinical development Q4 2017.
Subjects
Infectious DiseasesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Infectious Diseases & Therapy.
Research article · 5 May 2025
The Ultimate Cure for the COVID Syndemic
Mini review · 29 Apr 2025
COVID-19 Systematic Mini-Review as of April 2025
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Infectious Diseases & Therapy
- SubjectInfectious Diseases
- BylineArticles whose byline prints “Jamal Tazi”